• Dispose of or return the product: Customers are advised to either discard the affected bottles or return them to the retailer for a full refund.
• Consult a doctor: Patients taking ramipril should reach out to their healthcare provider for guidance on switching medications or obtaining new prescriptions.
• FDA resource: A complete list of affected bottles is available on the FDA website.

Broader Concerns with Indian-Made Drugs

This incident is the latest in a series of recalls tied to medications manufactured in India:

Cinacalcet Recall: Just weeks prior, Dr. Reddy’s Laboratories recalled over 330,000 bottles of cinacalcet tablets, used to treat hyperparathyroidism, due to the presence of cancer-causing impurities.

Contaminated Eye Drops: In 2022, eye drops made in India and sold under brands like EzriCare Artificial Tears caused a multi-state health crisis.

Over 80 infections, vision loss, and four deaths from sepsis were linked to bacterial contamination due to inadequate microbial testing and improper preservatives at the Global Pharma Healthcare facility.

Conclusion

While the current recall of ramipril is categorized as low-risk, it underscores ongoing concerns about the safety and quality control of pharmaceuticals manufactured in some overseas facilities. Patients taking ramipril should remain vigilant, consult their doctors promptly, and check the FDA’s list of recalled products to ensure their medication is safe.